Enabling custom solutions for downstream processing

Orjana Terova¹, Jing Zhu¹, Andy Tomlinson¹, Frank Detmers², Pim Hermans² and Jessica de Rooij²

1 Thermo Fisher Scientific, 35 Wiggins Ave, Bedford, MA, 01730, USA; 2 Thermo Fisher Scientific, J.H. Oortweg 21, 2333 CH, Leiden, Netherlands

Introduction

The manufacture of complex biotherapeutics, such as activated proteins or closely related product forms, requires novel purification strategies, which may not always exist. Our custom ligand and resin development platforms enable the development of innovative purification resins, providing a solution for challenging downstream processes. Here we present custom downstream processing solutions, developed in close collaboration with our customers, including a case study covering the single step purification of prothrombin. Custom resin production can start with affinity ligand development or with existing affinity ligands provided by the customer.

Custom POROS™ resin development

A customer-defined or custom developed affinity ligand, can be immobilized through surface chemistries that are aligned with application needs, on the POROS backbone.

POROS Chromatography Resins are rigid 50 micron polymeric beads characterized by the addition of large “throughpores”. The large pore structure makes these resins ideally suited for the capture of large biomolecules.

In addition, other resins such as ion exchange or reversed phase resins can be developed specific to your down stream processing needs.

Prototype resin development – Experimental design

1. Investigation of ligand immobilization to offer superior performance as it relates to capacity
   - Understand correlation between coupling yields and ionic capacity
   - Determine ligand charge/resin ratio.

2. Screening DoE study to further optimize coupling conditions
   - Understand which critical inputs during the coupling reaction impact resin performance
   - Determine coupling conditions.

3. Evaluating bead morphology impact in resin performance

CaptureSelect™ custom ligand development

We offer a unique, milestone-based service for the development of product- and/or process-specific affinity solutions tailored to a target protein and its specific requirements. The custom ligand can be further developed into an affinity resin, which can be used in large-scale processing of biopharmaceuticals. CaptureSelect ligands offer a unique affinity purification solution based on Camelid-derived single domain $\text{V}_{\text{H},\text{H}}$ antibody fragments.

CaptureSelect ligands are designed to meet the most challenging purification needs, such as closely related product forms or activated proteins.

Prothrombin – case study

Customer need:
- Reduction of chromatography steps in the purification process of prothrombin
- Mild elution conditions to maintain protein activity
- Selectivity for the most biologically active form of prothrombin (fully carboxylated form)

During the anion exchange chromatography process, the uncarboxylated variants of prothrombin elute in the pre-peak (AEC-HPLC). Comparison between anion exchange (QFF) and $\text{V}_{\text{H},\text{H}}$ affinity chromatography shows the $\text{V}_{\text{H},\text{H}}$ affinity resin has a very high selectivity for the most biologically active form of prothrombin. The single-step purification results in significant lower host cell protein content in the eluate, without compromising purity.

CaptureSelect development pipeline

Custom production of CaptureSelect affinity resins can start from library construction all the way to a cGMP suitable resin or from further development of a product from our development pipeline.

Influence of pore size on ionic and binding capacity

Resins of large pore size revealed lower ionic and binding capacity, due to their lower surface area.

Resins with smaller pore sizes show high ionic but lower binding capacity.

Resins from mid range pore size seem to be best candidate for the defined coupling conditions as binding capacity is higher.

Categorical data analysis: 2000 A³, 3000 A³, 4000 A³, 5000 A³, 6000 A³

- Ionic Capacity, umol/mL
- DA 40-mer binding capacity, mg/mL

Product Stage: Therapeutic proteins & viruses: Antibody types

- Research Use Only products
  - Human Growth Hormone (NGH), C-tagXL
  - Tissue plasminogen activator (IPA), Anthithrombin III, Fibrinogen (Fib), Tranfserin, Apolipoprotein H (ApoH), C1-inhibitor (C1-inh), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Lead Development
  - Prothrombin, Erythropoietin (EPO)
  - Adeno-Associated Virus multi serotype (AAVX), Adenosinovirus (AdVd)
- Lead Selection
  - Insulin, Thyroid-Stimulating Hormone (TSH), Influenza (H4), Deoxyribonuclease (DNase)
- Lead screening
  - Interferon and b (IFNa/b), Interleukin 2 (IL2), Factor V, FXI, FXII, and FH, Lentivirus (VSV-G)